Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

45.53
+2.225.13%
Post-market: 45.20-0.3300-0.72%19:59 EST
Volume:1.89M
Turnover:84.11M
Market Cap:3.91B
PE:-10.49
High:45.79
Open:42.88
Low:42.48
Close:43.31
Loading ...

Cathie Wood Takes Profit On Hot AI Stock Palantir Again, Continues To Sell Block Shares Amid Bitcoin Buzz

Benzinga
·
27 Dec 2024

Cathie Wood’s ARK Investment bought 58K shares of Crispr Therapeutics today

TIPRANKS
·
27 Dec 2024

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors

Zacks
·
27 Dec 2024

Institutional investors may adopt severe steps after CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 8.3% drop adds to a year losses

Simply Wall St.
·
25 Dec 2024

Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Zacks
·
23 Dec 2024

This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?

Motley Fool
·
23 Dec 2024

CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing

TIPRANKS
·
21 Dec 2024

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Zacks
·
21 Dec 2024

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

Zacks
·
17 Dec 2024

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

Motley Fool
·
17 Dec 2024

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
17 Dec 2024

Stock Market Today: Dow Jones Up As Bitcoin Play Pops; Cathie Wood Loads Up On This AI Stock Amid 48% Plunge

Blockhead
·
17 Dec 2024

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

Insider Monkey
·
15 Dec 2024

3 Things You Need to Know if You Buy CRISPR Therapeutics Today

Motley Fool
·
14 Dec 2024

2 Growth ETFs to Buy With $200 and Hold Forever

Motley Fool
·
13 Dec 2024

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

GlobeNewswire
·
13 Dec 2024